-
-
there is always RU and CB which block pretty much 100% dht. Is that not enough for you?
yeah that sounded promising the first time I've read it but it doesn't really apply to our case - "regenerate" is not for those with androgenic alopecia but with actual scars in places where follicles grows. Yes, apparently along with scar repair, follicles come back to life also but it likely won't work for AA cases.
this is a hair transplant boost
Histogen is all we got!!! It's pathetic reading you all discussing Aderans as if there is ANY CHANCE that it would work... There is none. Forget about itComment
-
Experimental treatments... Only a very small minority is willing to use those, if they have heard of them/have the expertise to use them. The more treatments on the legit market in the future, the better.
Well, I agree that it's too early to 'count on' any of these in-development treatments ever emerging as full products, as if its inevitable (we all know the history here) but it's hardly impossible that at least one or two will make it.Histogen is all we got!!!Comment
-
RU will never reach market. Too unstable and the patents are too close to expiry, and too unsafe around women.
CB may reach market, but it's not certain. A lot could still go wrong, both technologically (effectiveness, finding a vehicle) and most importantly financially (Cosmo might get bought out and CB would get shelved like so many other drugs that had potential). So it's good to have this HYG-440 as a back up.
They specifically cite MPB as one of their primary purposes. Their aim is to differentiate stem cells into hair cells. We know from Cotsarelis that the stem cells are still there in MPB. So if it works at all, it should work for MPB.yeah that sounded promising the first time I've read it but it doesn't really apply to our case - "regenerate" is not for those with androgenic alopecia but with actual scars in places where follicles grows. Yes, apparently along with scar repair, follicles come back to life also but it likely won't work for AA cases.
Aderans works. Just not very well, and only in 60% of people. On the results I've seen so far I wouldn't pay for it. The best use for it so far is to add density to make HT grafts go further.Histogen is all we got!!! It's pathetic reading you all discussing Aderans as if there is ANY CHANCE that it would work... There is none. Forget about itComment
-
Yes, phase III is predominantly about how well their procedure works in a large, heterogeneous group of trialists. In effect, they're attempting to mimic the diversity of patients they'll treat when the product goes to market. This way they (hopefully) uncover any idiosyncratic adverse events that could come up and they'll know the true overall efficacy.
I don't think aderans results look too bad. I'd like to see what they can do for someone who's just beginning to bald or someone who's diffuse. They might get much better results. However, a 60% responder rate is very low. Hopefully they're continuing research to figure out why the response rate is so low and can find a way to improve on that number.
Finding out you're in the 40% non responder group would be quite a bitter pill to take.Comment
-
Aderans is not about growth, or at least at this point, that isn't there goal. The reason for the 60% response rate is simply due to genetics. Only 60% of these people have genetics that can respond and make these hair follicles immune.
In essence, it's a much better alternative to Fin that permanently makes your hair immune to MPB. Mix it with Histogen and you could get great results.Comment
-
Replistoderans, ideally.Comment
-
I really don't understand how forums members have suddenly decided that aderans "immunizes" hair follicles to MPB. That has never been demonstrated experimentally. There has been no data to suggest this is even remotely possible; it's merely hypothetical speculation. And far fetched speculation at that. There has been talk that the injected cells would incorporate in the follicle structure and "somehow" change the entire geno and phenotypic expression of all the cells in that follicle. This would be quite the feat! One without precedent. And there is really no scientifically valid explanation to explain how a few injected cells will change the genetics of an entire functioning organ such as a hair follicle.
In regards to Aderan's clinical trial, It would take many years beyond the scope of a traditional clinical trial to demonstrate that follicles have been immunized to mpb. Furthermore, it would require scientific measurements that are beyond what they are doing with their current trials. Such as following the progress of specific follicles and how they fare over time. So, i respectfully have to disagree with you. Aderans is not about immunization, they are, and i believe they've said so themselves, about follicle rejuvenation. Which oddly, is a position 100% opposite of what they declared earlier - in that they said rejuvenation is not possible and neogenisis is what they were doing.
But, with that said, i do think they are showing some results. Be interesting to see if it's compoundable. And then if you consider it combined with something like histogen and maybe a transplant, there could for the first time in history, be a treatment option that could restore a lot of hair.Comment
-
Only dangerous for pregnant women. There is some systemic absorption of RU and at least one of the metabolites of RU is antiandrogenic, which is doubly bad news.
CB on the other hand is quickly metabolised to an inactive molecule. It should be much safer around women, though you would still want to keep it away.Comment
-
*****, would love for CB to come to market. Thanks for the reply by the way. Any idea what the expected timeline for CB is?Comment
-
Probably 2017 for alopecia formulation, maybe 2016 if we're lucky.
The acne formulation they are aiming to get out by 2015, but I suspect 2016 is more realistic.
I never understand why they all want to try the acne formulation first. There are already treatments for acne and, while it can be distressing for some suffers for sure, severe acne in need of treatment isn't nearly as common as MPB. Surely MPB is an order of magnitude bigger market at least?
There are still some risks. The biggest ones for CB are that either Cosmo gets bought out (like happened with NEOSH) or the 'major multinational pharmaceutical company' they are partnered with decides it's not economic and sits on the patent til it expires, as is happening with RU.
They also still need to come up with an effective vehicle. They don't have one yet.Comment
-
bump
10bloxComment
Tweet
Comment